Objectives This study aims to evaluate the impact of therapy assessment PET/computed tomography (CT) scan on the management of locally advanced pancreatic adenocarcinoma (LAPC), and the value of qualitative versus quantitative PET/CT interpretation for patient outcome prediction.
Objectives This study aims to evaluate the impact of therapy assessment PET/computed tomography (CT) scan on the management of locally advanced pancreatic adenocarcinoma (LAPC), and the value of qualitative versus quantitative PET/CT interpretation for patient outcome prediction.
Materials and methods Forty-two LAPC patients were retrospectively included. PET/CT was performed at a median of 4.6 weeks after completion of chemo ± radiotherapy to assess the primary treatment response. PET was interpreted visually using a qualitative five-point scale (Hopkins criteria for therapy assessment). Quantitative PET parameters including maximum and peak standardized uptake value (SUV max and SUV peak ), total lesion glycolysis, and metabolic tumor volume (MTV) were also measured using the gradient segmentation method. Kaplan-Meier and Cox regression analyses were performed.
Results Thirty-five patients were followed up until death. Therapy assessment PET/CT led to a change in the overall management of 22 (52.4%) patients, prompting surgical resection (eight patients), adding radiation therapy (eight patients), or starting palliative chemotherapy (six patients).
The median survival in patients with a negative or a positive PET scan, according to the Hopkins criteria, was 14.6 and 8.7 months, respectively (P = 0.06). The median quantitative thresholds of SUV peak 2.64 [hazard ratio (HR) = 2.67,
Introduction
As the fourth most prominent cause of cancer-related mortality in the USA, pancreatic cancer accounted for an estimated 39 590 deaths in 2014 [1] . Pancreatic adenocarcinoma is commonly presented as metastatic or locally advanced disease at diagnosis [2, 3] . The overall 5-year survival rate for pancreatic cancer is 6.7%, varying widely according to disease stage, with 21.5% for localized disease, 8 .6% for locally advanced disease, and 2.3% for metastatic disease [4] . Locally advanced pancreatic adenocarcinoma (LAPC) is initially treated with induction chemotherapy or concurrent chemoradiation therapy [2] . A response to initial therapy could prompt surgical exploration and subsequent resection of the tumor [5] .
Thus, post-treatment follow-up could provide management and survival advantages and is recommended in these patients [5] .
PET/computed tomography (CT) has been shown to have diagnostic and prognostic advantages in the staging and therapy assessment of pancreatic adenocarcinoma [2, [5] [6] [7] . Fluorine-18 fluorodeoxyglucose ( 18 F-FDG)-avidity and PET-based quantitative parameters of baseline PET/CT have been shown to be useful in therapy planning [5, 8] and in modification of the target volume and radiation field [2, 5, 9] , and are considered as [10] [11] [12] [13] prognostic indicators of survival in pancreatic adenocarcinoma [11] [12] [13] [14] [15] [16] . Although several studies support the high performance of therapy assessment PET/CT in improving the management and predicting the outcome of patients with various solid tumors [17, 18] , little is known about the value of 18 F-FDG-PET/CT in therapy assessment of pancreatic adenocarcinoma, particularly of LAPC [10, 19] . The objectives of this study were to establish the value of post-treatment PET/CT in the management of patients with unresectable LAPC treated with chemotherapy with or without radiotherapy and to investigate the prognostic significance of both qualitative (five-point visual scale, Hopkins criteria for therapy assessment [20] ) and quantitative PET in therapy response assessment in patients with LAPC and propose a combined volumetric scoring system correlated with survival.
Materials and methods

Eligible patients
The present study was performed under a waiver of informed consent as approved by the Institutional Review Board. The guidelines of the Health Insurance Portability and Accountability Act (HIPAA) were followed. The medical records of patients with histologically confirmed pancreatic cancer who underwent 18 F-FDG-PET/CT at our institutions between June 2003 and June 2013, as part of their management, were retrospectively reviewed. Of them, patients with unresectable locally advanced pancreatic cancer who were referred for therapy assessment PET/CT scan after the completion of primary intended treatment were eligible for inclusion. Primary treatments were adjuant chemotherapy and chemotherapy alone or combined with radiation. None of the patients had metastatic disease, and all were initially considered to have unresectable tumors according to the clinicians' discretion either by staging imaging (CT, MR, or PET/CT) or by exploratory laparotomy. The post-treatment 18 F-FDG-PET/CT studies were ordered at the treating clinician's discretion to assess response to therapy. The change in management was assessed by comparing the pre-PET/CT management plans with post-PET/CT management plans for individual patients. The PET/CT images were scored using a structured qualitative five-point scale for therapy response assessment of pancreatic lesions based on 18 F-FDG-PET uptake. The activity in the mediastinal blood pool was taken as the background. The images were scored according to the five-point qualitative Hopkins criteria ( Fig. 1) for therapy assessment. The five-point scale was dichotomized to negative (scores 1, 2, and 3) and positive (scores 4 and 5) results.
Reader qualifications: The PET/CT studies were retrieved from the institutional archiving system and were reviewed using MIM Vista viewing platform (version 6.3.2; MIM Software Inc., Cleveland, Ohio, USA). All images were interpreted independently by two boardcertified nuclear medicine physicians (reader 1, R.W., and reader 2, E.M.) who were blinded to the outcome, according to the structured qualitative five-point scale (Hopkins criteria). Reader 1 is a current clinical PET/CT fellow with nuclear medicine board certification, and reader 2 is a current third-year nuclear medicine resident who is already board-certified in nuclear medicine outside the USA. Any discrepancies were adjudicated, independently, by a third reader who is an associate professor of Radiology, board-certified in Nuclear Medicine and Radiology.
Quantitative parameters
One reader (R.W.) also extracted the quantitative 18 F-FDG-PET/CT parameters of the pancreatic tumor, blinded to the outcome. Quantitative 18 F-FDG-PET/CT parameters including maximum standardized uptake value (SUV max ), peak standardized uptake value (SUV peak ), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured using the gradient segmentation method with MIM vista software analysis suite (version 6.3.2; MimVista Software Inc., Cleveland, Ohio, USA). Once the region of interest had been segmented, SUV max , SUV peak , MTV, and TLG were semiautomatically calculated by the software.
Receiver operating characteristic curve analysis for 18 
F-FDG-PET/CT parameters:
The median values for SUV max , SUV peak , and volumetric parameters of 18 F-FDG-PET/ CT (MTV and TLG) were used as cutoff points for the estimation of death. In addition, using receiver operating characteristic curve analyses, the optimal cutoff values for each parameter were determined to differentiate those who survived after 12 months following post-therapy 18 F-FDG-PET/CT scan from those who died earlier.
Statistical analyses
Descriptive values were presented as mean SD or median [25th, 75th range] if the data were not normally distributed. Categorical variables were presented as frequency (percentage). The time to overall survival was measured from the date of the therapy assessment PET/CT scan until the date of death. Date of death was determined using a webbased mortality registry or available electronic medical records at our institution. The survival data for patients who were alive were censored at the last follow-up date at our institution. The Youden Index (J) was used to determine the optimum cutoff point for quantitative PET parameters in the receiver operating characteristic analysis: J = maximum (sensitivity + specificity −1). Patients were dichotomized on the basis of the qualitative Hopkins criteria (negative and positive groups) and quantitative PET parameters using optimum and median values for SUV max , SUV peak , TLG, and MTV (high and low groups). In each subgroup, survival probabilities were generated using Kaplan-Meier survival curves and compared using the Mantel-Cox log-rank test. Univariate and multivariate Cox regression analyses were performed considering death as the endpoints. The statistical significance level was set at P less than 0.05. Statistical analysis was performed using IBM SPSS Statistics 22.0 (IBM Corp., Armonk, New York, USA).
Results
Patients characteristics and follow-up
A total of 42 LAPC patients (31 men and 11 women) with a mean (SD) age of 66.4 (10) years were included in the study. Post-therapy 18 F-FDG-PET/CT scan was performed at a median of 4.6 weeks (range = 0.3-17.1 weeks) after completion of the primary intended treatment to monitor the disease response. Table 1 summarizes the demographics and clinical characteristics of the study population. Of a total of 42 patients, 35 (83.3%) died during the follow-up. The median follow-up duration from the date of therapy assessment PET/CT in all patients was 10.3 months (range: 1-39. 4 
months).
Post-treatment 18 F-FDG-PET/CT and change in treatment 18 F-FDG-PET/CT led to changes in the overall management of 22 of 42 (52.4%) patients. The management changes included prompt palliative chemotherapy or a new chemotherapeutic regimen (six patients, 14.3%), starting stereotactic body radiation therapy (SBRT) or adding radiation therapy to the previous protocol (eight patients, 19.1%), and, lastly, modifying the scope of the surgery (eight patients, 19.1%). In the last eight patients, post-treatment 18 F-FDG-PET/CT suggested locally resectable tumors without evidence of metastases, and as a result these patients underwent surgical tumor resection. Of these patients, one was found to have unresectable disease during surgery and was instead treated with chemotherapy.
Thirteen of 42 patients (30.9%) continued on the previous chemotherapy or radiation therapy protocol after therapy response 18 F-FDG-PET/CT evaluation. In five other patients (11.9%), the treatment was stopped because of patient preference (two patients), poor F-FDG-PET/CT parameters yielded a significant result for SUV peak (P = 0.035), TLG (P = 0.005), and MTV (P = 0.008), but not for SUV max (P = 0.20) (Fig. 3) .
Cox regression models were performed including the following variables: age, sex, race, serum level of post-treatment CA19-9, median SUV max , median SUV peak , median TLG, and median MTV. In univariate analysis, the median SUV peak 2.64 [hazard ratio (HR) = 2.67, P = 0.043], TLG 44.0 g (HR = 2.64, P = 0.007), and MTV 24.7 ml (HR = 2.57, P = 0.01) significantly predicted death during the follow-up period. In multivariate Cox regression analysis, the median SUV peak (HR = 6.15, P = 0.006), TLG (HR = 2.97, P = 0.01), and MTV (HR = 2.69, P = 0.03) remained significant predictors of overall survival even after adjustment for age, sex, race, and serum level of post-treatment CA19-9 ( Table 2 ).
To predict the risk for death within 12 months after the therapy assessment 18 F-FDG-PET/CT scan, the optimum cutoff points of 18 F-FDG-PET parameters were determined. Table 3 summarizes the optimum cutoff points, their corresponding sensitivity and specificity, and the 1-year survival probabilities in LAPC patients. An optimum threshold of 3.62 for SUV max had 73% sensitivity and 80% specificity in predicting those who survived after 12 months. The Cox regression analyses showed that the optimum SUV max (HR = 5, P = 0.001), SUV peak (HR = 4.18, P = 0.002), TLG (HR = 2.82, P = 0.01), and MTV (HR = 3.6, P = 0.003) could significantly predict death within 1 year following the therapy assessment 18 
F-FDG-PET/CT scan (Table 3).
Overall effect of 18 F-FDG-avidity and total tumor burden on survival
The combined predictive effect of 18 F-FDG-avidity and total tumor volume on survival was investigated by risk-grouping patients according to the median cutoff points of SUV peak and MTV values. Group I included patients with both SUV peak and MTV lower than the cutoff points (19 patients); group II included patients who had either SUV peak or MTV above the cutoff points (17 patients); and group III included patients who had both SUV peak and MTV above the cutoff points (six patients). The Kaplan-Meier survival curves were significantly different between these three subgroups (Fig. 4) 
Discussion
Treatment response is an important factor for management planning and prognosis in pancreatic adenocarcinoma, particularly for those with LAPC and borderline resectable disease [5, 7] . PET/CT-based metabolic response assessment following chemoradiation therapy is known to be superior to contrast-enhanced multidetector computed tomography in various tumors as it can effectively distinguish between treatment-induced fibrosis/necrosis and tumor progression [5, 17, 21] .
According to the current guidelines in pancreatic adenocarcinoma, contrast-enhanced multidetector computed tomography is considered the diagnostic imaging modality of choice for routine staging and has been shown to have higher sensitivity in nodal staging compared with PET/CT scans [22] [23] [24] . However, PET/CT is recommended for initial staging of high-risk patients and for those with indeterminate conventional imaging results [7] , and has been suggested to aid in determining the biological target volume for nonuniform radiotherapy dose prescription [5, 9, 22, 23] .
Moreover, as with other neoplasms, PET/CT is found to be useful in monitoring the response to therapy and in evaluating treatment efficacy and may affect patient management [6, 7, 25] . In LAPC, adequate assessment of resectability after chemotherapy or radiation treatment could validate surgical resection in those with regional control or metabolic responses, whereas rapid development of distant metastasis early after treatment could prompt palliative treatment [25] . In concordance with the limited literature published [7, 26] , this study showed that therapy assessment PET/CT can be beneficially used in LAPC to tailor future therapeutic approaches, in deciding whether to continue or withdraw current treatment.
Further, baseline and post-therapy PET parameters have been shown to correlate with prognosis in pancreatic adenocarcinoma [5] . A previous meta-analysis including 198 patients with pancreatic adenocarcinoma (six studies) . CI, confidence interval; CT, computed tomography; HR, hazard ratio; MTV, metabolic tumor volume; SUV max , maximum standardized uptake value; SUV peak , peak standardized uptake value; TLG, total lesion glycolysis.
Therapy assessment PET/CT in LAPC Sheikhbahaei et al. 235 reported that high baseline SUV max is a significant predictor of death (HR = 2.39, 95% CI: 1.57-3.63) [27] . Baseline SUV max , MTV, and TLG have consistently been reported as potential predictive factors for survival in LAPC [11] [12] [13] [14] [15] [16] 28] .
In contrast to initial PET/CT, there are not as many studies determining the role of therapy response PET/ CT in the prediction of outcome for LAPC patients after primary chemoradiation treatment [7] . A summary is presented in Table 4 [19, 25, [29] [30] [31] . Previous studies showed that patients with low 18 F-FDG uptake or reduction in 18 F-FDG-avidity (%change in SUV max ) in post-therapy PET/CT had higher survival [10, 19, 30] . In keeping with the current literature, this study showed that the quantitative parameters of post-therapy PET/ CT, including SUV peak , MTV, and TLG, are significant prognostic markers of survival in LAPC, even after adjustment for CA19-9 level at the time of the scan.
Our previous study had shown that the five-point qualitative interpretation (Hopkins criteria) can predict treatment response and outcome in head and neck squamous cell carcinoma [20] . In this study we investigated the predictive value of Hopkins criteria for survival outcomes in the therapy response assessment of patients with LAPC. Our results indicated that positive qualitative interpretation (Hopkins criteria) could not predict the overall survival of the patients. The lack of statistical significance is likely due to the small number of patients in our study, particularly in the negative group (scores 1, 2, and 3), as the Kaplan-Meier curves did not cross.
The present study is the first investigation, to our knowledge, to examine the value of the volumetric parameters of post-treatment PET/CT and to propose a combined quantitative scoring system based on the PET/ CT parameters for LAPC patient outcome prediction. In a similar study by Schellenberg et al. [29] , PET/CT was performed after one cycle of chemotherapy and before radiotherapy in 55 patients with LAPC. They indicated that high MTV is associated with lower survival time among LAPC patients. They also showed that the median survival in low-risk patients (low SUV max and low MTV) is significantly longer than that in the high-risk group (high SUV max and high MTV). Our result demonstrated that the scoring system combining F-FDG, fluorine-18 fluorodeoxyglucose; HR, hazard ratio; MTV, metabolic tumor volume; ROC, receiver operating characteristic; SN, sensitivity; SP, specificity; SUV max , maximum standardized uptake value; SUV peak , peak standardized uptake value; TLG, total lesion glycolysis. Log-rank P-value = 0.005
Cum survival
Kaplan-Meier survival plot by combined quantitative PET scoring result: overall survival (months) between patients who were scored as 0 (group I), those scored as 1 (group II), and those scored as 2 (group III) differed significantly (log-rank, P = 0.005). Group I (score 0) was defined as SUV peak AND MTV lower than median points; group II (score 1) was defined as SUV peak OR MTV higher than median points; and group III (score 2) was defined as SUV peak AND MTV above the median points. MTV, metabolic tumor volume; SUV peak , peak standardized uptake value.
18 F-FDG-avidity and total tumor burden is helpful in risk-grouping patients after treatment completion, as patients with both high SUV peak and MTV showed a more than five-fold increased risk for death compared with those with a low SUV peak and MTV. Although TLG is a product of mean SUV and MTV, this study suggested that using a combined quantitative PET/CT scoring system (SUV peak , and MTV) provides better prognostication than SUV, MTV, or TLG alone, and could serve as a surrogate marker for prediction of outcome in LAPC patients.
There were some limitations to our study. First, enrollment of patients over 10 years in a retrospective manner can be associated with inherent unavoidable biases. Although we did include patients with fairly similar clinical conditions, nonresectable LAPC, the nonuniform and heterogenous treatment regimens (various cycles of chemotherapy with or without radiation, and different maximum radiation doses) may have affected the survival of the patients and introduced biases. Besides, the wide range in time interval between the completion of primary treatment and the post-therapy PET/CT could represent a bias in comparing the results particularly in those treated with radiation therapy. The presence of a draining biliary stent in some patients could be another potential confounder, as these stents often demonstrate inflammatory uptake that might be confused if the tumor was in close proximity to the stent. Further, the quantitative segmentation was performed by one reader using a single vendor's commercial segmentation algorithm.
Conclusion
PET-based volumetric parameters can predict survival outcomes in patients with LAPC. A combined quantitative PET/CT scoring system based on SUVpeak and MTV could provide better prognostication. Table 4 Summary of studies evaluating the role of therapy assessment PET/CT in survival from pancreatic adenocarcinoma Therapy assessment PET/CT in LAPC Sheikhbahaei et al. 237
Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
